Xantho Biotechnology delegates participated in the BIO2024 in US San Diego together with the Taiwan representatives comprising government officials and other 40+ Taiwanese Biotech. During the 4-day event, Xantho Bio has attended the one- on-one partnering meetings with global pharma to discuss potential business collaboration and licensing opportunities, demonstrating strong demands for Xantho’s new drugs in the global market.
About Xantho Biotechnology Co., LTD
Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology.
The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal topical cream for treating inflammatory skin conditions including atopic dermatitis (AD) and plaque psoriasis. GM-XANTHO also has wound healing effects in skin conditions such as pressure ulcer, diabetic wound and burn wound. The IND for AD, plaque psoriasis and pressure ulcer have been approved by the USFDA.
We are looking to collaborate with pharmaceutical companies to offer a better drug for patients with unmet medical needs.